Lee Hyejoo, Lim Na Rae, Kim Seonwoo, Cho Hyun, Chung Woo Chul
Academic Research Service Headquarters, LSK Global PS, Seoul 04535, Republic of Korea.
Department of Internal Medicine, St. Vincent Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
J Clin Med. 2025 Sep 2;14(17):6209. doi: 10.3390/jcm14176209.
: Erosive gastritis has various causes, and severe damage to the mucosa can cause symptoms such as indigestion, abdominal pain, nausea, and vomiting. The condition is defined by visible erosions that emerge as discrete defects in the gastric mucosa. Stillen is a natural mucosal-protective agent derived from , but its comparative efficacy versus rebamipide remains unclear. This systematic review and network meta-analysis evaluated whether Stillen leads to non-inferior endoscopic improvement outcomes compared to rebamipide in patients with acute or chronic gastritis. : Databases including PubMed, EMBASE, Cochrane Library, RISS, KoreaMed, ClinicalTrials.gov, and ICTRP were searched through 15 August 2025. Eligible studies were randomized controlled trials (RCTs) comparing Stillen with rebamipide or other mucosal-protective agents in gastritis. Two reviewers independently screened studies, extracted data, and evaluated the risk of bias. The primary outcome was the improvement rate (≥50% erosion reduction); the secondary outcome was the cure rate (complete erosion resolution) and safety outcomes. A total of 11 RCTs met the inclusion criteria, with 9 contributing to the primary network analysis. Stillen was non-inferior to rebamipide in terms of the improvement rate at 2 weeks (OR: 1.11, 95% CI: (0.88, 1.39) in FAS) and in pooled analysis across 2, 3, and 4 weeks. Cure rates showed no significant differences between the two agents. The safety outcomes were comparable, with no significant differences. Most studies were assessed as having a low risk of bias, and the certainty of evidence was rated as high for most efficacy outcomes. The network meta-analysis suggests that Stillen is non-inferior to rebamipide in improving erosions in patients with acute or chronic gastritis.
糜烂性胃炎有多种病因，黏膜的严重损伤可导致消化不良、腹痛、恶心和呕吐等症状。该病症由胃黏膜中出现的离散性缺损即可见糜烂来定义。施维舒是一种源自[具体来源未给出]的天然黏膜保护剂，但其与瑞巴派特相比的疗效仍不明确。本系统评价和网状Meta分析评估了在急性或慢性胃炎患者中，施维舒与瑞巴派特相比是否能带来非劣效的内镜改善结果。：检索了包括PubMed、EMBASE、Cochrane图书馆、RISS、KoreaMed、ClinicalTrials.gov和ICTRP在内的数据库，检索截至2025年8月15日。符合条件的研究为比较施维舒与瑞巴派特或其他胃炎黏膜保护剂的随机对照试验（RCT）。两名评价员独立筛选研究、提取数据并评估偏倚风险。主要结局为改善率（糜烂减少≥50%）；次要结局为治愈率（糜烂完全消退）和安全性结局。共有11项RCT符合纳入标准，其中9项纳入主要网状分析。在2周时的改善率方面，施维舒不劣于瑞巴派特（全分析集[FAS]中比值比[OR]：1.11，95%置信区间[CI]：(0.88, 1.39)），在2、3和4周的汇总分析中也是如此。两种药物的治愈率无显著差异。安全性结局具有可比性，无显著差异。大多数研究被评估为偏倚风险较低，大多数疗效结局的证据确定性被评为高。网状Meta分析表明，在改善急性或慢性胃炎患者的糜烂方面，施维舒不劣于瑞巴派特。
